Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.4K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

880
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
880
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

631
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
631
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Social Contagion in Initiating Non-Suicidal Self-Injury in Schizophrenia: A Case Report.

Actas espanolas de psiquiatria·2026
Same author

Geospatial Patterning of Hypertension and High Cholesterol Prevalence in Inland Southern California: An Ecological ZIP-Code-Level Study.

Cureus·2026
Same author

The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review.

International journal of molecular sciences·2026
Same author

Caffeine Consumption Patterns Among Medical Students: Survey Study.

JMIR formative research·2026
Same author

A Review of the Mechanisms and Risks of <i>Panax ginseng</i> in the Treatment of Alcohol Use Disorder.

Diseases (Basel, Switzerland)·2025
Same author

Current Neuroethical Perspectives on Deep Brain Stimulation and Neuromodulation for Neuropsychiatric Disorders: A Scoping Review of the Past 10 Years.

Diseases (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jan 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

791

The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and

Jonathan Shaw1, Charles Lai1, Peter Bota1

  • 1School of Medicine, California University of Science and Medicine, Colton, CA 92324, USA.

Healthcare (Basel, Switzerland)
|October 16, 2025
PubMed
Summary
This summary is machine-generated.

Selective serotonin reuptake inhibitors (SSRIs) are used off-label for behavioral issues, but can cause sexual dysfunction. More research is needed to understand the risks and treatments for post-SSRI sexual dysfunction (PSSD).

Keywords:
SSRIhypersexualityimpulsivitymedication managementpsychiatry

More Related Videos

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

14.2K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:11

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

251

Related Experiment Videos

Last Updated: Jan 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

791
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

14.2K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:11

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

251

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed psychiatric medications.
  • A common side effect of SSRIs is sexual dysfunction.
  • SSRIs are used off-label to manage inappropriate sexual behaviors, but lack official guidelines.

Purpose of the Study:

  • To review the off-label use of SSRIs for managing inappropriate sexual behaviors.
  • To examine the mechanisms and consequences of SSRI-induced sexual dysfunction.

Main Methods:

  • Literature review using PubMed and Google Scholar.
  • Inclusion of peer-reviewed references on SSRI mechanisms, off-label use, and PSSD.
  • Consideration of grey literature, including one report from the UK's Care Quality Commission.

Main Results:

  • SSRIs may cause sexual dysfunction by inhibiting dopaminergic tone via serotonin receptors (e.g., 5-HT1A, 5-HT2A, 5-HT2C).
  • SSRIs are considered for off-label use in geriatric patients with dementia due to a favorable safety profile over antipsychotics.

Conclusions:

  • The off-label use of SSRIs for behavioral issues, especially in dementia patients, is common.
  • The risks and treatments for post-SSRI sexual dysfunction (PSSD) remain unclear, posing a significant risk as it can be severe and persistent.
  • High-quality clinical trials are necessary to address the current evidence base, which largely comprises case reports and theoretical papers.